183 related articles for article (PubMed ID: 35522027)
1. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer.
Leboulleux S; Lamartina L; Hadoux J; Baudin E; Schlumberger M
Expert Opin Investig Drugs; 2022 Jul; 31(7):669-679. PubMed ID: 35522027
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
4. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
5. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
6. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
7. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
[TBL] [Abstract][Full Text] [Related]
8. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
9. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
10. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
13. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
15. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
17. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
18. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.
Kaae AC; Kreissl MC; Krüger M; Infanger M; Grimm D; Wehland M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830100
[TBL] [Abstract][Full Text] [Related]
19. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
